- Home
- CCEL vs DTIL Comparison
CCEL vs DTIL Comparison
Compare CCEL & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- DTIL
- Stock Information
- Founded
- CCEL 1989
- DTIL 2006
- Country
- CCEL United States
- DTIL United States
- Employees
- CCEL N/A
- DTIL N/A
- Industry
- CCEL Managed Health Care
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- DTIL Health Care
- Exchange
- CCEL Nasdaq
- DTIL Nasdaq
- Market Cap
- CCEL 51.9M
- DTIL 43.3M
- IPO Year
- CCEL 1997
- DTIL 2019
- Fundamental
- Price
- CCEL $5.62
- DTIL $5.33
- Analyst Decision
- CCEL Strong Buy
- DTIL Strong Buy
- Analyst Count
- CCEL 1
- DTIL 3
- Target Price
- CCEL $8.50
- DTIL $37.67
- AVG Volume (30 Days)
- CCEL 11.9K
- DTIL 196.8K
- Earning Date
- CCEL 04-15-2025
- DTIL 05-12-2025
- Dividend Yield
- CCEL 4.59%
- DTIL N/A
- EPS Growth
- CCEL N/A
- DTIL N/A
- EPS
- CCEL 0.01
- DTIL 1.04
- Revenue
- CCEL $32,102,750.00
- DTIL $68,696,000.00
- Revenue This Year
- CCEL $2.21
- DTIL N/A
- Revenue Next Year
- CCEL $0.98
- DTIL $30.20
- P/E Ratio
- CCEL $603.61
- DTIL $5.19
- Revenue Growth
- CCEL 2.33
- DTIL 40.98
- 52 Week Low
- CCEL $4.96
- DTIL $3.61
- 52 Week High
- CCEL $9.50
- DTIL $13.44
- Technical
- Relative Strength Index (RSI)
- CCEL 42.26
- DTIL 55.37
- Support Level
- CCEL $5.37
- DTIL $4.90
- Resistance Level
- CCEL $5.93
- DTIL $5.75
- Average True Range (ATR)
- CCEL 0.51
- DTIL 0.37
- MACD
- CCEL 0.04
- DTIL 0.11
- Stochastic Oscillator
- CCEL 46.81
- DTIL 74.55
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.